Stockscreener 앱 받기
11.24
4.74%
0.28
전일 마감가:
$10.96
열려 있는:
$11.26
하루 거래량:
11,921
Relative Volume:
0.09
시가총액:
$270.83M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+9.23%
1개월 성능:
+9.54%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.74
$11.52
1주일 범위
$10.00
$11.57
52주 변동 폭
$9.68
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
명칭
Artiva Biotherapeutics Inc
전화
(858) 267-4467
주소
5505 MOREHOUSE DRIVE, SAN DIEGO
ARTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ARTV | 11.31 | 270.83M | 0 | 0 | 0 | 0.00 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.84 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 개시 | Jefferies | Buy |
| 2024-08-13 | 개시 | Needham | Buy |
| 2024-08-13 | 개시 | TD Cowen | Buy |
| 2024-08-13 | 개시 | Wedbush | Outperform |
Artiva Biotherapeutics Inc 주식(ARTV)의 최신 뉴스
Cantor Fitzgerald Forecasts ARTV FY2024 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2024 Earnings - MarketBeat
Wedbush Has Bearish Estimate for ARTV FY2024 Earnings - Defense World
Wedbush Lowers Earnings Estimates for Artiva Biotherapeutics - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Issues Quarterly Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Artiva Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC - MarketBeat
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
Artiva Bio to Present at Jefferies Healthcare Conference, Spotlight on Cell Therapy Pipeline | ARTV Stock News - StockTitan
Artiva Biotherapeutics (NASDAQ:ARTV) vs. Iovance Biotherapeutics (NASDAQ:IOVA) Critical Review - Defense World
Cell therapy developer Artiva refiles for a $100M IPO - MSN
Artiva Biotherapeutics appoints new board member By Investing.com - Investing.com Australia
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - ForexTV.com
Artiva Biotherapeutics, Inc. Appoints Alison Moore as an Independent Member of Its Board of Directors - Marketscreener.com
Artiva Biotherapeutics appoints new board member - Investing.com
Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4%Time to Sell? - MarketBeat
Wall Street SWOT: Artiva Biotherapeutics stockNK cell pioneer targets autoimmune market By Investing.com - Investing.com South Africa
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Artiva Biotherapeutics (NASDAQ:ARTV) Trading 6.2% Higher - MarketBeat
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Quiet Period Will End on August 28th - Defense World
Artiva Biotherapeutics, Inc.'s Quiet Period Set To Expire on August 28th (NASDAQ:ARTV) - MarketBeat
Brokers Issue Forecasts for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV) - MarketBeat
Analysts Set Expectations for Artiva Biotherapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Quotes, Forecast and News Summary - Benzinga
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch - Benzinga
Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at TD Cowen - Defense World
Needham & Company LLC Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Wedbush Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Cantor Fitzgerald - Defense World
Non-Hodgkin Lymphoma Drugs Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc - Barchart
July IPOs to Watch in Tech, Biotech, Food Security and Transportation - Investorideas.com newswire
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares - 24/7 Wall St.
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal - Seeking Alpha
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Yong-Jun Huh Buys 2,083,332 Shares - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Global Strategic Fund I. Venbio Purchases 416,666 Shares - Defense World
VenBio fund acquires $5m in Artiva Biotherapeutics stock By Investing.com - Investing.com Australia
VenBio fund acquires $5m in Artiva Biotherapeutics stock - Investing.com India
Artiva Biotherapeutics sees major stock purchases by GC Corp entities - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO By Investing.com - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO - Investing.com India
Artiva Biotherapeutics Inc (ARTV) 재무 분석
Artiva Biotherapeutics Inc (ARTV)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):